Inflammatory mechanisms in pulmonary disease

GROUP INFORMATION

Inflammation and repair process in lung disease. Chronic obstructive pulmonary disease (COPD). Apnoea/hypoapnoea syndrome. Idiopathic pulmonary fibrosis (IPF). Immunopathogenesis. Molecular diagnosis. Cellular diagnosis. New therapeutic techniques. New models in care.

Pulmonary diseases are a major social and healthcare issue, related to their high prevalence and associated mortality. In recent years, our group has worked on various aspects related to lung diseases, as reflected in our publications in collaboration with other working groups.

General aims:

  1. Promoting research in pulmonary diseases.
  2. Promoting care quality in treating patients with chronic lung disease.
  3. Promoting research knowledge transfer in lung disease.
  4. Creating new lines of research in collaboration with other groups.

Our research interests: The Pneumology Department at Hospital de La Princesa is part of the Biomedicine R&D Programme. Hospital Universitario de La Princesa ConSEPOC-CM: Inflammation and hypoxia: mechanisms of COPD and SAHS development and progression (S2010/BMD-2542). Julio Ancochea heads up the group (COPD- HLPR), which includes other members of IIS-Princesa. The role of this group in the project has focused on selecting, characterising, monitoring and taking samples of peripheral blood, induced sputum and exhaled breath condensate from patients with COPD and SAHS.

Several active clinical trials will be conducted in the next few years looking at different lung diseases (COPD, asthma, idiopathic pulmonary fibrosis, bronchiectasis and cystic fibrosis).

  • Making advances in developing, maintaining and strengthening the chronic respiratory disease group at IIS-Princesa (IP).
  • Incorporation of a new senior clinical researcher into our group (J.B. Soriano) through the UAM- Linde Healthcare Chair.
  • Completing the European M-BREATH study (COPD Monitoring and Biomarkers) requested by the European Union’s Horizon 2020 programme.
  • TackSHS Horizon 2020 proposal submitted. Tackling secondhand smoke emissions from electronic cigarettes: assessing exposure, new interventions, impact in pulmonary diseases and economic burden for different European populations. The TackSHS project. Topic innovation and research: Global Alliance for Chronic Diseases. Prevention and treatment of pulmonary diseases. Reference: HCO-06-2015
  • Submit the IMPACTOR proposal to the Horizon 2020 programme. Smart health platform for self-management and predictive monitoring of asthma, chronic obstructive pulmonary disease (COPD) and associated comorbidities.
Team members

area-1-Linea-7-G22-Dr-AncocheaGroup leader:

Julio Ancochea Bermúdez

Hospital Universitario La Princesa

  Other team members:

  • Tamara Alonso Pérez. Hospital Universitario de La Princesa.
  • Ana Laura Capote Moreno. Hospital Universitario de La Princesa.
  • Carolina Cisneros Serrano. Hospital Universitario de La Princesa.
  • Rosa María Girón Moreno. Hospital Universitario de La Princesa.
  • Rosa Mar Gómez Punter. Hospital Universitario de La Princesa.
  • Pedro Landete Rodríguez. Hospital Universitario de La Princesa.
  • María Teresa Pastor Sanz. Hospital Universitario de La Princesa.
  • María Patricia Pérez González. Hospital Universitario de La Princesa.
  • Pilar Rubio Bueno. Hospital Universitario de La Princesa.
  • Joan B. Soriano Ortiz. Universidad Autónoma de Madrid.
  • Claudia Valenzuela. Hospital Universitario La Princesa.
  • Enrique Domingo Zamora García. Hospital Universitario de La Princesa.

Girón Moreno, Rosa María. Epidemiology and clinical/microbiological characterisation of acute exacerbations in patients with bronchiectasis not caused by cystic fibrosis. SEPAR. 2014-2016.

Ancochea Bermudez, Julio. Design and local implementation of clinical audits in different types of old (DELICATO). PI13/01993. ISCIII. 2014-2016.

Ancochea Bermúdez, Julio. CONSEPOC: Inflammation and hypoxia: mechanisms of development and progression of COPD and SAHS. S2010/BMD-2542. CAM. 2012-2015.

Ancochea Bermúdez, Julio. CHAIN phenotype study of cardiovascular risk factor in chronic obstructive pulmonary disease. SEPAR and Astra Zeneca. 2011-2016.

Girón Moreno, Rosa María. Creation of a bronchiectasis database. SEPAR. 2012-2015.

Girón Moreno, Rosa María. Epidemiology and clinical/microbiological characterisation of acute exacerbations in patients with bronchiectasis not caused by cystic fibrosis. SEPAR. 2014-2016.

Gómez Punter, Rosa. Relationship between radiological alterations, quality of life and exacerbations in adult patients with cystic fibrosis. SEPAR. 2015-2018.

Zamora García, Enrique Domingo. Study of hypoxia-inducible factors (HIF) in chronic obstructive pulmonary disease (COPD) for identifying non-invasive diagnostic and prognostic biomarkers. SEPAR. 2014-2017.

Girón Moreno, Rosa María. Study of the role of cellular glycosaminoglycans from the pulmonary epithelium in the development of infections associated with cystic fibrosis. SEPAR. 2015-2017.

Soriano Ortiz, Joan B. TackSHS: Tackling secondhand smoke in Europe: assessment of SHS exposure according to policies, attributable disease and economic burden, and impact of interventions for reducing the exposure. TackSHS: 681040. European Commission. 2015-2019.

Ancochea Bermudez, Julio. Identification and evaluation of hypoxia-related biomarkers for non-invasive diagnosis of non-alcoholic fatty liver disease and associated vascular damage. PI17/00535. ISCIII. 2018-2020.

The aim of the project is to determine the prevalence of non-alcoholic fatty liver disease and cardiovascular disease in patients with sleep apnoea-hypopnoea syndrome.

This grant is funded by the 2013-2016 Spanish Science, Technology and Innovation Research Plan and the ISCIII – Subdirectorate General for Evaluation and Promotion of Research – and co-financed by the European Regional Development Fund, Operational Programme Smart Growth 2014-2020 according to Regulation (EU) no. 1303/2013.

logo-feder

Landete Rodríguez, Pedro. Role of hypoxia in the pathogenesis of metabolic and cardiovascular comorbidities associated with the most prevalent chronic respiratory diseases: Diagnostic and prognostic use of new serum biomarkers. 073/2015. SEPAR. 2016-2019.

Gómez Punter, Rosa Mar. Use for prognostic evaluation of hand grip mortality in patients with chronic obstructive pulmonary disease. 2017-2019.

Vázquez Espinosa, Emma. Effort capacity, physical activity and nutritional status in COPD patients. 2016- 2017.

Gómez Punter, Rosa Mar. DECAF score as a predictor of mortality and its relationship to the CAT quality of life questionnaire in patients with a COPD diagnosis. 2017.

Rubio Bueno, Pilar. Efectividad de la Cirugía Maxilomandibular mediante Distracción Osteogénica Mandibular en la Apnea Obstructiva del Sueño: Un abordaje quirúrgico Innovador Mínimamente Invasivo. PI18/01891. ISCIII. 2019-2021.

Determinar la efectividad en el control de la sintomatología y en la corrección de parámetros clínicos de un nuevo abordaje quirúrgico mínimamente invasivo de avance de la mandíbula mediante Distracción Osteogénica en pacientes diagnosticados de síndrome de apnea hipopnea del sueño (SAHS).

This grant is funded by the 2017-2020 Spanish Science, Technology and Innovation Research Plan and the ISCIII – Subdirectorate General for Evaluation and Promotion of Research – and co-financed by the European Regional Development Fund, Operational Programme Smart Growth 2014-2020 according to Regulation (EU) no. 1303/2013.

Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR, INPULSIS Trial Investigators. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. N Engl J Med 2014. 370: 2071-2082. FI: 55.873(Q1). PMID: 24836310. DOI: 10.1056/NEJMoa1402584.

López-Campos JL, Hartl S, Pozo-Rodriguez F, Roberts CM, European COPD Audit team. Variability of hospital resources for acute care of COPD patients: the European COPD Audit. Eur Respir J 2014. 43: 754-762. FI: 7.636(Q1). PMID: 23988775. DOI: 10.1183/09031936.00074413.

Segrelles Calvo G, Girón Moreno RM, Muñoz Vázquez A, Gago A, Ancochea J. Peripheral Polyneuropathy in a Patient With Severe Chronic Obstructive Pulmonary Disease. Arch Bronconeumol 2012. 48: 484-0. FI: 1.372(Q4). PMID: 22704528. DOI: 10.1016/j.arbres.2012.04.020.

Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM, CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. LANCET 2011. 377: 1760-1769. FI: 38.278(Q1). PMID: 21571362. DOI: 10.1016/S0140-6736(11)60405-4.

Raghu, Ganesh, Collard, Harold R., Egan, Jim J., Martinez, Fernando J., Behr, Juergen, Brown, Kevin K., Colby, Thomas V., Cordier, Jean-Francois, Flaherty, Kevin R., Lasky, Joseph A., Lynch, David A., Ryu, Jay H., Swigris, Jeffrey J., Wells, Athol U., Ancochea, Julio, Bouros, Demosthenes, Carvalho, Carlos, Costabel, Ulrich, Ebina, Masahito, Hansell, David M., Johkoh, Takeshi, Kim, Dong Soon, King, Jr., Talmadge E., Kondoh, Yasuhiro, Myers, Jeffrey, Mueller, Nestor L., Nicholson, Andrew G., Richeldi, Luca, Selman, Moises, Dudden, Rosalind F., Griss, Barbara S., Protzko, Shandra L., Schuenemann, Holger J., ATS ERS JRS ALAT Comm. An Official ATS/ERSARS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am J Respir Crit Care Med 2011. 183: 788-824. FI: 11.080(Q1). PMID: 21471066. DOI: 10.1164/rccm.2009-040GL.